A study has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal type of brain cancer.

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a prominent figure in age-reversal science, disclosed significant findings from a preclinical study focusing on progeria, an uncommon genetic disorder ...